(RTTNews) - Vor Bio (VOR), a clinical-stage biotechnology company reported its second-quarter 2026 financial results today and provided a corporate update, with investors focusing on continued Phase 3 progress for telitacicept and a cash runway extending into early 2029.
Recent Business & Clinical Updates:
Vor Bio's Phase 3 UPSTREAM MG trial evaluating telitacicept in generalized myasthenia gravis remains on track, with topline results anticipated in 1H 2027.
Enrollment is also ongoing in the global Phase 3 UPSTREAM SjD trial evaluating telitacicept in primary Sjögren's disease.
China's National Medicinal Products Administration approved telitacicept for the treatment of adult patients with Sjögren's disease and IgA nephropathy, marking its fourth and fifth commercial approvals in China.
Results from the Phase 3 TELIGAN trial evaluating telitacicept in IgA nephropathy were published in The New England Journal of Medicine. Vor Bio also appointed David Zaccardelli, Pharm.D., former CEO and President of Verona Pharma, to its Board of Directors.
Q2 2026 Performance:
Vor Bio reported R&D expenses of $25.9 million, compared with $261.5 million in Q2 2025. The decrease was primarily due to the $222.6 million expense related to the Telitacicept License Agreement recorded in Q2 2025, along with costs associated with employee and lease terminations.
General and administrative expenses increased to $21.9 million, compared with $12.8 million in the prior-year quarter, primarily due to higher stock-based compensation, personnel-related expenses and commercial costs.
Net loss narrowed significantly to $62.8 million, compared with a net loss of $1.57 billion in Q2 2025, primarily reflecting changes in the fair value of outstanding liability-classified warrants.
The Road Ahead:
The key near-term catalyst remains the Phase 3 UPSTREAM MG trial, with topline results expected in 1H 2027.
Vor Bio is also advancing the Phase 3 UPSTREAM SjD trial in primary Sjögren's disease as it seeks to expand telitacicept's potential applications across autoimmune diseases.
The company is developing telitacicept, a dual BAFF/APRIL inhibitor, across major autoantibody-driven conditions, with the goal of supporting potential regulatory approvals in the United States, Europe and Japan.
Cash Position:
Vor Bio held $466.1 million in cash, cash equivalents and marketable securities as of June 30, 2026. Including $48.4 million in net proceeds from at-the-market sales during July, the company expects a pro-forma cash and investment balance of approximately $514.5 million, providing a projected runway into early 2029.
VOR is currently trading at $23.01, down 1.41%.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
